By using, you agree to our terms and use of cookies to enhance your experience.

Novo Nordisk

GLP-1 cost-effectiveness study published

6th January 2017

Liraglutide 1.2 mg has proved “cost-effective” compared to alternative daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK, a study has ...

Read more

Global diabetes child care programme extended

1st December 2016

A programme which provides children wth type 1 diabetes around the world free access to insulin and treatment has been extended. The Changing Diabetes® in Children initiative will continue for ...

Read more

Study shows Xultophy boosts glycaemic targets

21st September 2016

Adults with type 2 diabetes treated with Xultophy® (insulin degludec/liraglutide) are up to 4.5 times more likely to achieve glycaemic targets without hypoglycaemia and weight gain, research has ...

Read more

Hypo kit safety alert issued

6th September 2016

Batches of a kit used to treat severe hypoglycaemic reactions are being recalled due to safety issues. Users of the GlucaGen HypoKit are being asked to check whether they have an affected product ...

Read more

Tresiba® now available in Scotland

9th August 2016

An alternative treatment to help improve glycaemic control for adults living with diabetes is now available in Scotland. NHS Scotland can now prescribe Novo Nordisk’s Tresiba® (insulin degludec), ...

Read more

Novo publishes positive Victoza® results

14th June 2016

The GLP-1 receptor analogue Victoza® (liraglutide) significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial, Novo Nordisk has ...

Read more

Tresiba significantly lowers hypo rates

13th June 2016

New results from two Phase 3b trials have shown people with type 1 and type 2 diabetes  treated with Tresiba® (insulin degludec) experienced significantly lower rates of several types of ...

Read more